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ABSTRACT
Mono-isocentric volumetric-modulated arc therapy (VMAT) can be used to treat multiple brain metastases. It
remains unknown whether mono-isocentric VMAT can improve the dose distribution compared with dual-
isocentric dynamic conformal arc therapy (DCAT), especially for two brain metastases. We compared the dose
distribution between dual-isocentric DCAT and mono-isocentric VMAT for two large brain metastases, and ana-
lyzed the relationship between the distance between the two targets and the difference in dose distribution.
A total of 19 patients, each with two large brain metastases, were enrolled. The dose prescribed for each plan-
ning target volume (PTV) was 28 Gy in ﬁve fractions (D99.8 = 100%). We created new indices derived from
conformity indices suggested by the Radiation Therapy Oncology Group (RTOG; mRTOG-CI) and Paddick
et al. (mIP-CI), using the dosimetric parameters of the sum of the two PTVs. The median PTV was 5.05 cm3
(range, 2.10–28.47). VMAT signiﬁcantly improved mRTOG-CI and mIP-CI compared with DCAT. In all cases,
VMAT was able to improve mRTOG-CI and mIP-CI compared with DCAT. Whereas the normal brain volume
receiving 5 Gy was similar between the two modalities, the normal brain receiving 10, 12, 15, 20, 25 and 28 Gy
(V10–V28) was signiﬁcantly smaller in VMAT. The mean beam-on times were 213.3 s and 121.9 s in DCAT and
VMAT, respectively (P < 0.001). Mono-isocentric VMAT improved the target conformity and reduced the
beam-on time and V10–V28 of the normal brain for not only two close metastases but also two distant metasta-
ses. Mono-isocentric VMAT seems to be a promising treatment technique for two large brain metastases.
Keywords: dynamic conformal arc therapy; volumetric-modulated arc therapy; two brain metastases; dosimetric
comparison
INTRODUCTION
Brain metastases are reported to occur in 20–40% of cancer patients
during the course of their illness [1]. Various treatment modalities
exist for brain metastases, such as surgical resection, whole-brain
radiotherapy (WBRT), stereotactic radiosurgery (SRS), hypofractio-
nated stereotactic radiotherapy (HFSRT), chemotherapy, molecular
targeted therapy, and best supportive care. SRS for multiple brain
metastases is a well-established treatment option and includes
linear-accelerator (LINAC)-based radiosurgery and gamma knife
radiosurgery (GKS) [1, 2]. Whereas GKS can treat more than 10
lesions at the same time, conventional LINAC-based radiosurgery
using dynamic conformal arc therapy (DCAT) can usually irradi-
ate only 1–4 brain metastases [3]. Because multiple isocenters
must be set for each lesion in patients with multiple brain
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metastases in conventional LINAC-based radiosurgery systems
using DCAT, the treatment time increases as the number of iso-
centers increases.
Radiotherapy technology has advanced rapidly in recent years,
and it is now possible to utilize mono-isocentric volumetric-modu-
lated arc therapy (VMAT) instead of DCAT for multiple brain
metastases. Only one isocenter is required for mono-isocentric
VMAT to treat multiple targets, and the treatment time for mono-
isocentric VMAT is increasingly shorter than that for DCAT as the
number of targets increases. Since it takes a long treatment time to
treat more than two brain metastases by DCAT, it appears as
though it would be desirable to use mono-isocentric VMAT for
more than two brain metastases, in institutions with LINAC. On
the other hand, two brain metastases can be treated by either
mono-isocentric VMAT or dual-isocentric DCAT within a tolerable
treatment time in the clinical setting. Although data on the treat-
ment outcomes and dosimetric parameters for mono-isocentric
VMAT for multiple brain metastases have already been reported,
few patients with two brain metastases were included in these stud-
ies, and it remains unknown whether mono-isocentric VMAT can
achieve a better dose distribution compared with dual-isocentric
DCAT, especially for two brain metastases [4–11]. For cases with
two nearby brain metastases, mono-isocentric VMAT seems to
achieve higher target conformity using an inverse planning method
compared with dual-isocentric DCAT. On the other hand, for cases
with two distant metastases, dual-isocentric DCAT may be more
suitable compared with mono-isocentric VMAT because mono-
isocentric VMAT generates a low-dose spill, and the irradiated vol-
ume of the normal brain increases [8]. Therefore, it is necessary to
analyze the relationship between the distance between the two tar-
gets and the difference in dose distributions between DCAT and
VMAT.
VMAT can also be a good modality for large intracranial tumors.
In GKS and conventional LINAC–based radiosurgery systems, the
prescribed dose for large brain metastases should be reduced com-
pared with that for small targets in view of the severe late side
effects, especially radiation necrosis; as a result, the local control
rate is worsened [12, 13]. Using inverse planning methods, VMAT
can achieve better target conformity and reduce the dose to the sur-
rounding normal tissue compared with the conventional treatment
system. Therefore, VMAT appears to be suitable for large or irregu-
lar intracranial lesions [11, 14]. Additionally, HFSRT can also
achieve good local control for large brain metastases, and HFSRT
with VMAT can be achieved safely using a frameless image-guided
system (BrainLAB AG, Feldkirchen, Germany) in a LINAC-based
radiotherapy system within a short treatment time [15, 16].
Although it appears that mono-isocentric hypofractionated stereo-
tactic VMAT could be the best treatment option for large brain
metastases, most reports regarding mono-isocentric VMAT for mul-
tiple brain metastases have addressed only small targets with one
fraction [4–10].
In this context, we conducted a planning study to compare the
dose distribution between dual-isocentric DCAT and mono-
isocentric VMAT for two large brain metastases in the setting of
HFSRT.
MATERIALS AND METHODS
This study followed all the dictates of the Declaration of Helsinki,
and our Institutional Ethical Review Board approved the research
(Approval number E2276). Written consent was obtained from the
patients.
Patient population
Sixty patients with two metastatic brain tumors were treated with
SRS or HFSRT at our institution from January 2008 to July 2016.
In our department, planning target volumes (PTVs) that exceed
2.0 cm3 are treated by HFSRT, not only to improve the local con-
trol rate but also to reduce late severe toxicity. Thus, among the
patients described above, 19 consecutive patients with two PTVs
>2.0 cm3 were included in this study.
Contouring
Patients were immobilized in thermoplastic masks, and planning
computed tomography (CT) images with a thickness of 1.25 mm
were acquired by a Light Speed RT scanner (GE Healthcare,
Milwaukee, WI, USA). Contouring and treatment planning were
performed using Eclipse version 11.0.47 (Varian Medical Systems,
Palo Alto, CA, USA). Contrast-enhanced magnetic resonance
imaging (MRI) scans were fused with the planning CT images.
The PTV was deﬁned as the gross tumor volume plus a 1 mm
margin to allow for set-up errors, as well as inter- and intrafractional
errors. The lenses, eyes, optic nerves, chiasm, brainstem, and normal
brain were contoured as organs at risk (OARs). Treatment couch
structures were included in the dose calculation.
Treatment planning
Dual-isocentric DCAT and mono-isocentric VMAT plans were cre-
ated for each of the 19 cases. Flattening ﬁlter-free 6 MV photon
beams of a Varian TrueBeamSTx LINAC (Varian Medical Systems)
were used in all plans. The dose rate was set at 1400 monitor units
(MU) per minute. The Acurous XB dose calculation algorithm was
employed using a calculation grid size of 1.0 mm. The prescribed
dose for each target was set at 28 Gy in 5 fractions. The maximum
doses to the brainstem/optic nerve/chiasm and lens were set at less
than 20 Gy and 10 Gy in 5 fractions, respectively.
Dual-isocentric DCAT plans
Two isocenters were set at the centres of each PTV, and two plans
were created for each target. The DCAT plan consisted of one
coplanar and two non-coplanar arcs to each target (total, six arcs).
For each target, one coplanar arc rotated from 181° to 179° with a
collimator angle of 0°, and two non-coplanar arcs were placed at
couch angles of 60° and 300°. One non-coplanar arc rotated from
20° to 160°, whereas the other non-coplanar arc rotated from 200°
to 340° with a collimator angle of 0°(Fig. 1).
We modiﬁed the leaf margin, which was the distance from the
PTV to the ﬁeld’s edge, to ensure that D99.8 = 100% (i.e. 99.8% of
each PTV was covered by 100% of the prescribed dose) in the sum
of the two plans. The maximum dose (Dmax) for each target was set
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within 40 ± 1 Gy, meaning that each PTV was covered by almost
70% of the Dmax. The same leaf margin was applied in all directions
to each PTV, while the value was manually modiﬁed to ensure that
the Dmax was set within 40 ± 1 Gy for each PTV.
Mono-isocentric VMAT plans
VMAT plans were created by one coplanar and two non-coplanar
arcs with one isocenter (total, three arcs) using the RapidArc system
(Varian Medical Systems). The isocenter was set at the centre of
the two PTVs. One coplanar arc was rotated from 181° to 179°
with a collimator angle of 45°. The gantry’s rotation, the angle of
the couch, and the angle of the collimator of the two non-coplanar
arcs were the same as those used in the DCAT plans. The jaw track-
ing system (Varian Medical Systems) was employed in all plans.
Optimization was performed to satisfy the following criteria: two
PTVs were covered by ≥99.8% of the prescribed dose (thus,
D99.8 ≥ 100%), the Dmax for each target was set within 40 ± 1 Gy,
and the doses to the normal brain and OARs were reduced as far as
possible.
Evaluation of treatment plans
We evaluated the target conformity, beam-on time, MU, irradiated
volume of the normal brain, and mean dose to the normal brain.
We also evaluated the D2% to the OARs except for the normal
brain, where D2% was the dose to 2% of the volume of the OARs.
The beam-on time was calculated by taking into account the
dose rate, gantry rotation, and gantry speed.
With regard to the irradiated volume of the normal brain, we
evaluated V5, V10, V12, V15, V20, V25 and V28, where Vx refers to the
volume of the normal brain irradiated by more than x Gy.
The conformity indices deﬁned by the Radiation Therapy
Oncology Group (RTOG-CI) and Paddick et al. (IP-CI) are usually
used to evaluate the conformity for intracranial tumors [17, 18].
However, in cases with particularly large and close lesions, RTOG-
CI and IP-CI cannot be calculated because the isodose line of the
prescribed dose can be merged and cannot be separated for each
target. Thus, we created new indices derived from RTOG-CI and
IP-CI using the dosimetric parameters of the sum of the two PTVs
to evaluate the target conformity. One index was a modiﬁed version
of RTOG-CI (mRTOG-CI), deﬁned as V(28)/VPTVs, where V
(28) was the volume enclosed by an isodose line of 28 Gy, and
VPTVs was the sum of the two PTVs. The other was a modiﬁed
IP-CI (mIP-CI), deﬁned as ([VPTVs(28)]2/[V(28) × VPTVs]),
where VPTVs(28) was the sum of two PTVs receiving more than
28 Gy (Fig 2).
We calculated the distance between the two targets, the dif-
ference in mRTOG-CI/mIP-CI between DCAT and VMAT
(ΔmRTOG-CI/ΔmIP-CI), and the improvement ratio of VMAT
to DCAT in mRTOG-CI/mIP-CI (r-mRTOG-CI/r-mIP-CI). The
differences in V5/V10/V12/V15/V20/V25/V28 (ΔV5–V28) between
DCAT and VMAT were also calculated. ΔmRTOG-CI/ΔmIP-CI/
ΔV5–V28 refers to the difference between the value of VMAT
minus the value of DCAT in mRTOG-CI/mIP-CI/V5–V28, respect-
ively. r-mRTOG-CI/r-mIP-CI was deﬁned as follows: r-mRTOG-
CI = {|(mRTOG-CI in VMAT) – 1| – |(mRTOG-CI in DCAT) –
1|}/|(mRTOG-CI in DCAT) – 1|, and r-mIP-CI = {|(mIP-CI in
VMAT) – 1| – |(mIP-CI in DCAT) – 1|}/|(mIP-CI in DCAT) – 1|
(Fig. 3).
The distance between the two targets was deﬁned as the dis-
tance between each centroid position of the two PTVs.
Statistical analysis
All statistical analyses were performed with the aid of EZR, which is
a graphical user interface for R (the R Foundation for Statistical
Computing, Vienna, Austria, version 3.2.2) [19]. More precisely,
EZR is a modiﬁed version of R commander version 1.32, facilitating
biostatistical evaluations.
Data from the DCAT and VMAT plans were compared with the
Shapiro–Wilk test, the Wilcoxon signed-rank test, and a paired
t test. The following relationships were analysed using Spearman’s
rank correlation coefﬁcient: the difference between dosimetric para-
meters and the distance between the two targets, the difference
between dosimetric parameters and VPTVs, the distance between
the two targets and r-mRTOG-CI/r-mIP-CI, and the difference
between the VPTVs and r-mRTOG-CI/r-mIP-CI. A P-value of
<0.05 was considered to indicate statistical signiﬁcance.
RESULTS
The median PTV was 5.05 cm3 (range, 2.10–28.47 cm3). The mean
mRTOG-CI/mIP-CIs were 1.32/0.75 and 1.17/0.85 in DCAT and
Fig. 1. Arc arrangements of dual-isocentric dynamic
conformal arc therapy (DCAT) and mono-isocentric
volumetric-modulated arc therapy (VMAT).
Fig. 2. The concept of the modiﬁed RTOG-CI (mRTOG-CI)
and modiﬁed IP-CI (mIP-CI.
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VMAT, respectively. Because both mRTOG-CI and mIP-CI of
VMAT were closer to 1, indicating more conformal dose distribu-
tion, VMAT signiﬁcantly improved the target conformity compared
with DCAT (Table 1). In all cases, including not only the cases
with two close metastases but also the cases with two distant metas-
tases, VMAT was able to improve mRTOG-CI and mIP-CI com-
pared with DCAT. The mean MUs were similar between the two
groups. The mean beam-on times were 213.3 and 121.9 s in DCAT
and VMAT, respectively (P < 0.001).
Although there was no signiﬁcant difference between the two
groups for the normal brain V5 and the mean dose to the normal
brain, the mean of V10–V28 was signiﬁcantly reduced in VMAT
(Table 2).
The Spearman’s rank correlation coefﬁcients of the relationships
between ΔmRTOG-CI/ΔmIP-CI/ΔV5–V28, r-mRTOG-CI/r-mIP-
CI, VPTVs and the distance between the two targets are shown in
Table 3. There was a weak correlation, in which absolute Spearman’s
coefﬁcients were from 0.2 to 0.4, between the distance and
r-mRTOG-CI/r-mIP-CI/ΔV10–V28. Moderate or high correlations,
in which absolute Spearman’s coefﬁcients were from 0.4 to 1, were
found between the VPTVs and ΔmIP-CI/r-mRTOG-CI/r-mIP-CI/
ΔV10–V28.
Scatter plots of r-mRTOG-CI/r-mIP-CI, the distance between
the two targets, and VPTVs are shown in Fig. 4. There were weak
correlations between the distance and r-mRTOG-CI/r-mIP-CI, and
moderate or high correlations were seen between the VPTVs and
ΔmIP-CI/r-mRTOG-CI (Fig. 4). The sagittal plane of the dose dis-
tribution for a representative case is shown in Fig. 5.
The mean D2% of the brainstem, chiasm, right optic nerve, left
optic nerve, and right lens were similar between the two techniques.
The mean D2% of the right eye, left eye and left lens were 1.4/1.7,
1.0/1.8 and 0.7/1.2 Gy in DCAT/VMAT, respectively. Although
the mean D2% of the right eye, left eye and left lens in VMAT were
statistically signiﬁcantly higher compared with DCAT, the absolute
values of those structures were far below the tolerance dose of each
structure in both of the groups.
DISCUSSION
We conducted a planning study to compare the dose distribution
between dual-isocentric DCAT and mono-isocentric VMAT for two
large brain metastases. VMAT was able to achieve signiﬁcantly bet-
ter conformity within a shorter treatment time compared with
DCAT, and the normal brain V10–V28 was signiﬁcantly reduced in
VMAT. VMAT improved the target conformity and reduced the
dose to the normal brain not only for two close metastases but also
for two distant metastases. VMAT could, therefore, be a promising
treatment modality for two large brain metastases.
Mono-isocentric VMAT has recently been used for patients with
multiple brain metastases [5, 6, 9]. Multiple metastases can be trea-
ted with mono-isocentric VMAT using advanced radiotherapy tech-
niques, including ﬁne multileaf collimators, jaw tracking systems,
and sophisticated optimization methods. Whereas the dosimetric
comparison showed the superiority of VMAT compared with
DCAT regarding target conformity and the irradiated normal brain
volume for multiple brain metastases, there were very few cases, and the
volume and number of target lesions varied in these studies [10, 11].
Fig. 3. The calculation of r-mRTOG-CI and r-mIP-CI.
Table 1. Indices of target conformity, monitor units and
beam-on time
DCAT VMAT
Index (Mean ± SD) P-value
mRTOG-CI 1.32 ± 0.07 1.17 ± 0.06 <0.001
mIP-CI 0.75 ± 0.04 0.85 ± 0.04 <0.001
MU 2376 ± 313 2584 ± 355 0.071
Beam-on time (s) 213.6 ± 1.4 116.3 ± 11.6 <0.001
DCAT = dynamic conformal arc therapy, VMAT = volumetric-modulated arc
therapy, SD = standard deviation, mRTOG-CI = modiﬁed conformity index (CI)
derived from the CI deﬁned by the Radiation Therapy Oncology Group
(RTOG) [17], mIP-CI = modiﬁed CI derived from the CI deﬁned by Paddick
et al. [18], MU = monitor units.
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To our knowledge, this is the ﬁrst study to report a better dose distribu-
tion in mono-isocentric VMAT compared with dual-isocentric DCAT,
particularly for two large brain metastases.
The beam-on time of VMAT was signiﬁcantly shorter than that
of DCAT even for two PTVs, and it was almost half that of DCAT
in our study. In the present study, only the beam-on time was evalu-
ated for the treatment time. Mono-isocentric VMAT will addition-
ally shorten the treatment time compared with dual-isocentric
DCAT for the following two reasons. First, mono-isocentric VMAT
could reduce the total number of arcs compared with dual-
isocentric DCAT. A reduced number of arcs enables shortening of
the treatment time needed to rotate the couch and the gantry for
each arc. Second, there is no need to move the isocenters one after
another in mono-isocentric VMAT. The time for moving one iso-
center and the need for geometric veriﬁcation at the other isocenter
can be omitted in mono-isocentric VMAT. Reduced treatment time
could make the intrafractional error small, improve patients’
throughput, and relieve patients’ distress. Even if patients have only
two intracranial lesions, mono-isocentric VMAT could be the appro-
priate modality.
The VMAT technique is also useful for large brain metastases.
When large brain metastases are treated by SRS with one fraction, the
prescribed dose should be reduced for large brain metastases in con-
sideration of the risk of brain necrosis, and the local control rate
becomes unsatisfactory as a result [12, 13]. Some of the challenges of
large brain tumors involve improving local control as well as reducing
toxicity, which includes the use of multisession GKS, LINAC-based
HFSRT and LINAC-based HFSRT with VMAT [14, 15, 20, 21]. Our
results showed a moderate-to-high correlation among the VPTVs,
ΔmIP-CI, r-mRTOG-CI, r-mIP-CI and ΔV10–V28, which means that
VMAT improved the dose distribution as the PTV increased.
Although there is no clear evidence regarding the most appropriate
modality for large brain metastases, HFSRT with mono-isocentric
VMAT could be a good modality for two large brain metastases.
Mono-isocentric VMAT could reduce the dose to the normal
brain and may reduce the risk of radiation-induced brain necrosis.
V10–V28 was signiﬁcantly lower in VMAT in the present study. As
some patients need to receive intracranial re-irradiation due to intra-
cranial recurrence, it seems sensible to set the dose to the normal
brain as low as possible.
To evaluate the conformity index for multiple lesions that are
located close to one another, we created new conformity indices
derived from RTOG-CI and IP-CI. Our data showed that V28 was
reduced in VMAT, and mRTOG-CI and mIP-CI were also
improved in VMAT. The results may support the view that the
modiﬁed indices are useful for evaluating target conformity for two
lesions. However, there are still no adequate indices for multiple
intracranial targets, and further discussion regarding suitable con-
formity indices is needed.
Whereas VMAT seems to improve conformity with the inverse
planning method, particularly for patients with two close lesions,
our study showed only a weak correlation between the distance and
r-mRTOG-CI/r-mIP-CI, and no apparent correlation between the
distance and ΔmRTOG-CI/ΔmIP-CI. This means that VMAT can
improve target conformity for patients with not only two close
metastases but also two distant metastases. Although VMAT gener-
ates a low-dose spill, there was no apparent correlation between the
distance and ΔV5 [8]. This may be due to the fact that setting the
dose to the normal brain as low as possible and the use of a jaw
tracking system may succeed in reducing the low-dose spill despite
the distance between the two targets.
Table 2. Irradiated volume of the normal brain and mean
dose to the normal brain
DCAT VMAT
Volume (cm3) (Mean ± SD) P-value
V5 180.80 ± 101.32 163.18 ± 99.18 0.096
V10 51.91 ± 31.88 44.13 ± 26.74 <0.001
V12 37.56 ± 23.25 30.94 ± 18.36 <0.001
V15 24.85 ± 15.48 19.96 ± 11.92 <0.001
V20 13.52 ± 8.79 10.08 ± 5.85 <0.001
V25 7.14 ± 5.19 4.33 ± 2.24 <0.001
V28 4.19 ± 3.31 1.79 ± 0.93 <0.001
Mean dose (Gy) 2.60 ± 0.90 2.53 ± 0.76 0.872
DCAT = dynamic conformal arc therapy, VMAT = volumetric-modulated arc
therapy, SD = standard deviation, Vx = the volume of the normal brain receiving
x Gy.
Table 3. Indices of Spearman’s rank correlation coefﬁcients












DCAT = dynamic conformal arc therapy, VMAT = volumetric-modulated arc
therapy, mRTOG-CI = modiﬁed conformity index (CI) derived from the CI
deﬁned by the Radiation Therapy Oncology Group (RTOG) [17], mIP-CI =
modiﬁed CI derived from the CI deﬁned by Paddick et al. [18], VPTVs = the
sum of the two planning target volumes, Vx = the volume of the normal brain
receiving x Gy, Δ = the value of VMAT minus the value of DCAT. r-mRTOG-
CI/r-mIP-CI was deﬁned as follows:
r-mRTOG-CI = {|(mRTOG-CI in VMAT) – 1| – |(mRTOG-CI in DCAT) – 1|}/
|mRTOG-CI in DCAT) – 1|
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The mean D2% of the right eye, left eye and left lens were statis-
tically signiﬁcantly higher in VMAT compared with DCAT.
However, the absolute values of those structures were far below the
tolerance dose of each structure in both groups. Therefore, the dif-
ferences in the mean D2% of the right eye, left eye and left lens
between the two groups were considered to be clinically non-
signiﬁcant. Mono-isocentric VMAT could be the better modality
compared with DCAT, even taking the doses to the OARs into
account, because mono-isocentric VMAT signiﬁcantly improved tar-
get conformity and shortened treatment time.
There are several limitations to our study. First, this planning
study compared dose distributions only between dual-isocentric
DCAT and mono-isocentric VMAT, and it is unclear whether the
higher conformity and lower dose to the normal brain of mono-
isocentric VMAT could reduce the toxicity in a clinical setting.
Second, this planning study did not compare the dose distribution
between mono-isocentric VMAT and GKS. Some reports showed
that GKS was superior to mono-isocentric VMAT with regard to
low-dose radiation spillage to the normal brain, whereas another
report suggested that the low-dose spillage to the normal brain, con-
formity, and dose fall-off between the two modalities were similar
[4, 7, 8]. Further dosimetric assessments (stratiﬁed by the number
of tumors, tumor volume, and treatment devices) between mono-
isocentric VMAT and other modalities seem to be necessary.
Finally, mono-isocentric VMAT must be performed using non-
coplanar multiple arcs to achieve high conformity. To deliver non-
coplanar beams, radiotherapists must enter the treatment room to
rotate the couch. Rotating the couch can increase the total treat-
ment time and further increase the risk of inducing nausea and
motion in the patient. As Dynamic WaveArc therapy (DWA)
Fig. 4. Scatter plots of the improvement ratio of modiﬁed RTOG-CI (mRTOG-CI) and modiﬁed IP-CI (mIP-CI), the
distance between the two targets, and the sum of the two planning target volumes (VPTVs). The improvement ratios of
VMAT to DCAT in mRTOG-C/mIP-CI are r-mRTOG-CI/r-mIP-CI, respectively. mRTOG-CI = modiﬁed conformity index
(CI) derived from the CI deﬁned by the Radiation Therapy Oncology Group (RTOG), mIP-CI = modiﬁed CI derived from
the CI deﬁned by Paddick et al.
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realized by the Vero4DRT (Mitsubishi Heavy Industries, Tokyo,
Japan; BrainLAB, Feldkirchen, Germany) can irradiate volumetric-
modulated sequential non-coplanar arc beams without rotating the
couch [22], DWA can omit the time needed to rotate the couch
and thus relieve distress in patients receiving mono-isocentric
VMAT for multiple brain metastases. DWA might be a good candi-
date for multiple brain metastases.
In conclusion, we conducted a planning study to compare the
dose distribution between dual-isocentric DCAT and mono-
isocentric VMAT for two large brain metastases. VMAT improved
the target conformity and reduced the beam-on time and V10–V28
of the normal brain for not only two close metastases but also two
distant metastases. As the PTV increased, VMAT improved the
dose distribution. Mono-isocentric VMAT could be the best modal-
ity in patients with two large brain metastases.
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